Revolutionary Advancements in Mammography AI: Lifesaving Breakthroughs
October 02, 2023
Every October, we shine a spotlight on breast cancer during National Breast Cancer Awareness Month. Thanks to the remarkable innovations in AI (Artificial Intelligence), we have more reasons to raise awareness about advancements in mammography than ever before. AI-powered mammography is revolutionizing care for patients' breast health by finding cancers earlier, with greater accuracy and efficiency, standardizing assessments of breast density, and offering personalized evaluations for each patients’ risk of developing breast cancer in the next 1 – 2 years.
Improved Accuracy and Peace of Mind
Much like the significant s... Continue reading
Embracing Clarity: Celebrating the 2nd Annual World Dense Breast Day
September 27, 2023
At iCAD, we are recognizing the 2nd annual World Dense Breast Day today, a day that holds significant importance, not only for the women who may have dense breasts but for all of us dedicated to advancing breast health awareness and early cancer detection.
As we gather to mark this event, it's essential to reflect on how far we've come in the journey towards eradicating the shadows that cancer casts. At iCAD, we're committed to creating a world where cancer can't hide. And this year, we have some exciting developments to share, especially concerning one of the strongest and most prevalent breast cancer risk factors—dense brea... Continue reading
Health Canada Grants Device License for iCAD's ProFound Risk 2.0, Revolutionizing Breast Cancer Risk Via a 1-2 Year Assessment
August 16, 2023
NASHUA, N.H., August 16, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions,
today announced Health Canada has issued a device license for ProFound Risk version 2.0,
the latest version of iCAD's personalized 1-2 year breast cancer risk assessment
solution.
"We are delighted to receive the device license from
Health Canada for the latest version of ProFound Risk, marking a major
milestone in our mission to help women worldwide know where and when breast
cancer may be hiding," sa... Continue reading
iCAD Reports Financial Results for Second Quarter Ended June 30, 2023
August 14, 2023
Company to host conference call and webcast today at 4:30 PM ET
NASHUA, N.H. – August 14, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June 30, 2023.
Highlights:
iCAD signs 20-year worldwide development and commercialization agreement with Google Health to integrate Google’s AI technology with its ProFound Detection for 2D Mammography for use upon regulatory approval as an independent reader for breast cancer screening.iCAD signs strategic multi-yea...
Continue reading
Joining Forces with Google to Revolutionize Breast Cancer Screening Worldwide
August 14, 2023
by Dana Brown, President and CEO of
iCAD, Inc.
We’ve joined forces with Google Health once
again to address two of the most pressing challenges in healthcare: the
global radiologist shortage and significant disparities in healthcare.
Per our 20-year worldwide agreement, Google's AI
technology will seamlessly integrate into our ProFound Breast
Health Suite, including ProFound
Detection, for use as an independent reader for breast cancer screening
with 2D... Continue reading
iCAD and Google Health Expand Integration of Google’s AI Technology with iCAD’s ProFound Breast Health Suite for 2D Mammography for Use as Independent Reader
August 14, 2023
Worldwide commercialization agreement offers potential
to ease radiologist workload and reduce healthcare disparities for women
NASHUA, N.H., August 14, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions,
today announced it signed an amendment to its development and commercialization
agreement with Google Health, which will enable
iCAD to integrate Google’s AI technology with its ProFound Breast
Health Suite for 2D Mammography for use worldwide upon regulatory appr... Continue reading
iCAD to Report Second Quarter 2023 Financial Results on August 14, 2023
July 31, 2023
NASHUA, N.H., July 31, 2023 -- iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions,
today announced it will release financial results for the second quarter of
2023 and host a conference call at 4:30 PM ET on Monday, August 14, 2023.
Earnings call details are as follows:
Domestic: 888-506-0062
International:
973-528-0011
Participant
Access Code: 460678
Continue reading
iCAD Signs Strategic Commercial Agreement with Radiology Partners, the Nation’s Largest Radiology Practice
July 18, 2023
Agreement positions iCAD as Radiology Partners’ breast AI provider, expanding potential for iCAD’s technology to reach millions of women in the U.S.
NASHUA, N.H., July 18, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it has signed a new strategic multi- year commercial agreement with Radiology Partners, the nation’s largest radiology practice through its owned and affiliated practices.
Under the agreement, which was executed on June 27, Radiology Partners selected iCAD as its provider of breast AI technologies deployed t... Continue reading
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Cleveland Clinic
July 12, 2023
Cleveland Clinic breast radiologist, Laura Dean, MD, to
discuss how iCAD’s Breast AI Suite helps her detect the breast cancers
radiologists fear most
NASHUA, N.H., July 12, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced its “ProFound Insights, ProFound Impact” webinar series will feature Dr.
Laura Dean, a renowned breast radiologist at the Cleveland Clinic. Titled “How Cleveland Clinic is
Finding the Breast Cancers Radio... Continue reading
iCAD Offers ROI Analysis Based on Real-World Results from its ProFound Breast AI Suite at AHRA Annual Meeting
July 10, 2023
Company’s ROI Tool offers preview of business value the
ProFound Breast AI Suite offers to clinicians and imaging facilities
NASHUA, N.H., July 10, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions,
today announced it is showcasing its ProFound AI Suite of clinically proven
solutions for breast cancer detection, density assessment, and short-term risk evaluation
in booth #228 at the AHRA 2023 annual meeting, taking place July 9-12 in
Ind... Continue reading
iCAD’s Breast AI Suite Wins U.S. General Services Administration’s AI Healthcare Challenge Award
May 18, 2023
Company presented portfolio of breast cancer
detection, density assessment and risk evaluation solutions at the competition,
focused on improving health outcomes
NASHUA, N.H., May 18, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced its Breast AI Suite is a winner of the U.S. General Services
Administration’s (GSA) “AI Healthcare Challenge” award. iCAD presented its portfolio
of breast cancer detection, density assessment and risk evaluation solutions at
the competiti... Continue reading
iCAD Reports Financial Results for First Quarter Ended March 31, 2023
May 15, 2023
Company to host conference call and webcast today at
4:30 PM ET
NASHUA,
N.H. – May 15, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology
leader providing innovative cancer detection and therapy solutions, today
reported its financial and operating results for the three months ended March
31, 2023.
Highlights:
Body of evidence supporting iCAD’s technologies grows, with compelling new research supporting Company’s Breast AI Suite and...
Continue reading
New Long-Term Real-World Research Confirms Xoft Skin eBx is as Safe and Effective as Mohs Surgery
May 11, 2023
98.9% of patients treated with Xoft remained
recurrence-free at a median follow-up of 7.6 years, according to recent study published
in Journal of Contemporary Brachytherapy
NASHUA, N.H., May 11, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced compelling new long-term real-world research confirms Xoft Skin eBx
is as safe and effective as Mohs surgery for the treatment of non-melanoma skin
cancer (NMSC). In the longest-term study of Xof... Continue reading
iCAD Showcases Breast AI Suite at Society of Breast Imaging Symposium, World’s Largest Breast Imaging Conference
May 03, 2023
iCAD’s AI solution minimizes interval cancers and
overcomes challenges associated with digital breast tomosynthesis
NASHUA, N.H., May 3, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced it will showcase its Breast AI Suite of cancer detection, density
assessment and risk evaluation solutions at the world’s largest breast imaging
conference, the Society of Breast Imaging (SBI) Symposium, taking place May 4-7
in National Harbor, MD. Attendees are i... Continue reading
iCAD to Report First Quarter 2023 Financial Results on May 15, 2023
May 01, 2023
NASHUA, N.H., May 1, 2023 -- iCAD, Inc. (NASDAQ: ICAD), a
global medical technology leader providing innovative cancer detection and
therapy solutions, today announced that it will release financial results for
the first quarter ended March 31, 2023, after the market close, and host a
conference call at 4:30 PM Eastern Time on Monday, May 15, 2023.
Earnings call details are as follows:
Domestic: 877-545-0523
International: 973-528-0016
Continue reading
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Boca Raton Regional Hospital
April 25, 2023
Kathy Schilling, MD, Boca Raton Regional Hospital, to
discuss how ProFound AI helped nine dedicated breast radiologists find 23% more
cancers, without increasing the rate of recalls
NASHUA, N.H., April 25, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced its “ProFound Insights, ProFound Impact” webinar series will feature Kathy
Schilling, MD, Medical Director, Christine E. Lynn Women's Health &
Wellness Institute, Boca Raton Regional Hospital. The live event,... Continue reading
New and Real-World Clinical Evidence Confirms ProFound AI Increases Cancer Detection and Reveals Critical Clues to Inform Clinical Decisions
April 20, 2023
New research presented at American Roentgen Ray Society (ARRS) meeting continues to validate unique value iCAD’s deep-learning breast AI solution offers to clinicians and patients
NASHUA, N.H., April 20, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced new real-world research confirms ProFound AI® has been proven to
increase cancer detection rates and provide vital clues for breast imagers'
clinical decisions through two studies. One... Continue reading
iCAD Strengthens Leadership Team with Appointment of Chief Financial Officer and New Senior Executives
April 17, 2023
Eric Lonnqvist as Chief Financial Officer, Vasu
Avadhanula as Chief Product Officer, and Michelle Strong as Chief Operations
Officer bolster the Company’s executive leadership team and accelerate the
Company’s growth strategies
NASHUA, N.H., April 17, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced the Board of Directors has approved the appointment of Eric Lonnqvist
as Chief Financial Officer (CFO), effective immediately, as well as Vasu Avadhanula
as Chief Pro... Continue reading
ProFound AI Risk Outperforms Traditional, Widely-Accepted Breast Cancer Risk Models for Both Short-term and Long-term Risk Assessments
April 04, 2023
ProFound AI Risk offered higher accuracy than Tyrer-Cuzick
v8 for all women, regardless of menopausal status, breast density, and family
history of breast cancer
NASHUA, N.H., April 4, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced new clinical evidence published in the Journalof Clinical Oncology found ProFound AI® Risk for 2D Mammography
is more accurate than Tyrer-Cuzick v8, a commonly used lifestyle risk model,
for both short-term... Continue reading
iCAD Reports Financial Results for Fourth Quarter ended December 31, 2022 and Year End
March 28, 2023
Strategy focused on profitability by end of 2024,
using current cash on hand
New leadership to host conference call and webcast
today at 4:30 PM ET
NASHUA, N.H. – March 28, 2023 – iCAD, Inc. (NASDAQ:
ICAD), a global medical technology leader providing innovative cancer
detection and therapy solutions, today reported its financial and operating
results for the twelve months ended
December 31, 2022.
Highlig... Continue reading
100 Comments